Is there a microangiopathic antiphospholipid syndrome?

Annals of the Rheumatic Diseases

Volumn 66, Issue 4, 2007, Pages 429-432

  Asherson, Ronald A ^a   Pierangeli, Sylvia S ^b   Cervera, Ricard ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; VASCULAR CELL ADHESION MOLECULE 1;

ANTIPHOSPHOLIPID SYNDROME; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIUM CELL; HELLP SYNDROME; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; MALIGNANT HYPERTENSION; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; HUMANS; MICROCIRCULATION; TERMINOLOGY; THROMBOSIS;

EID: 34147201358     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067033     Document Type: Editorial

References (88)

1. Asherson RA, Merry P, Acheson JF, Harris EN, Hughes GRV. Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the "primary" antiphospholipid syndrome. Ann Rheum Dis 1989;48:358-61.
2. Asherson RA. Subungual splinter hemorrhages: a new sign of antiphospholipid coagulopathy? Ann Rheum Dis 1990;49:268.
3. Francès C, Piette JC, Saada V, Papo T, Wechsler B, Chosidow O, et al. Multiple subungual splinter hemorrhages in the antiphospholipid syndrome: a report of five cases and review or the literature. Lupus 1994;3:123-8.
4. Francès C, Piette JC, Asherson RA. Dermatological aspects of antiphospholipid antibody syndrome. In: Sarzi Puttini P, Doria A, Girolomoni G, Kuhn A, eds. Handbook of systemic autoimmune diseases. Vol 5. Amsterdam, Elsevier 2006:103-118.
5. Von Landenberg P, Asherson RA, Piette JC. Renal, hepatic and other intraabdominal manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld J, eds. The antiphospholipid syndrome 11. Amsterdam: Elsevier Science, 2002:189-204.
6. Asherson RA. A "primary" antiphospholipid syndrome? J Rheumatol 1988;15:1742-6.
7. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508-12.
8. Piette J-C, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y, et al. The catastrophic antiphospholipid syndrome - Asherson's syndrome. Ann Med Interne (Paris) 2003;154:195-196.
9. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features or 50 patients. Medicine (Baltimore) 1998;77:195-207.
10. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001;80:355-77.
11. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Ashersons) syndrome. Immunobiology 2005;210:727-33.
12. Symmers W. Thrombotic microangiopathic haemolytic anemia (thrombotic microangiopathy). BMJ 1952;2:897-903.
13. Brain MC, Dacie JV, Hourihane DO. Microangiopathic hemolytic anemia. The possible role of vascular lesions in pathogenesis. Br J Haematol 1962;8:358-74.
14. Kokori SI, Ioannides JP, Voulgarelis M, Tzoufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med 2000;108:198-204.
15. Dold S, Singh R, Sarwar H, Menon Y, Candia LA, Espinoza R. Frequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: distinction from thrombotic thrombocytopenic purpura. Prognosis and outcome. Arthritis Rheum 2005;6:982-5.
16. Jain R, Chartash E, Susin M, Furie R. Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum 1991;24:173-82.
17. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol 1991;18:1916-18.
18. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol 1992;19:1474-8.
19. Nesher G, Hanna VE, Moore TL, Hersh M, Osborn TG. Thrombotic microangiopathic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994;24:165-72.
20. Umibe T, Nawata Y, Mori N Kanai H, Takabayashi K, Iwamoto T, et al. Thrombotic thrombocytopenic purpura (TTP) observed in a patient with primary antiphospholipid antibody syndrome. Ryumachi 1994;34:981- 7.
21. Musa MO, Nounou R, Sahovic E, Seth P, Qadi A, Aljurf M. Fulminant thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus and phospholipid autoantibodies. Eur J Haematol 2000;64:433-5.
22. Kincaid-Smith P, Fairly KF, Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 1988;68:795-815.
23. Matsuda J, Sanaka T, Gohchi K, Matsui K, Uchida S, Matsumoto M, et al. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand-factor cleaving protease. Lupus 2002;11:463-4.
24. Amoura Z, Costedoat-Chalimeau N, Veyradier A, Wolf N, Ghillani-Dalbin P, Cacoub P, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum 2004;50:3260-4.
25. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004;63:730-6.
26. Kniaz D, Eisenberg GM, Elrad H, Johnson CA, Valaitis J, Bregman H. Postpartum hemolytic uremic syndrome associated with antiphospholipid antibodies. Case report and review of the literature. Am J Nephrol 1992;12:126-33.
27. Ardiles LG, Olavarria F, Elgueta M, Moya P, Mezzano S. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: a possible pathogenetic role. Nephron 1998;78:278-83.
28. Meyrier A, Becquemont L, Weill P, Callard P, Rainfray M. Hemolytic-uremic syndrome with anticardiolipin antibodies revealing paraneoplastic systemic scleroderma. Nephron 1991;59:493-6.
29. Omstein MH, Rand JH. An association between refractory HELLP syndrome and antiphospholipid antibodies during pregnancy: a report of 2 cases. J Rheumatol 1994;21:1360-4.
30. Ilbery M, Jones AR, Samson J. Lupus anticoagulant and HELLP syndrome complicated by placental abruption, hepatic, dermal and adrenal infarct. Aust N Z J Obstet Gynaecol 1995;35:215.
31. McMahon LP, Smith J. The HELLP syndrome at 16 weeks gestation: possible association with the antiphospholipid syndrome. Aust N Z J Obstet Gynaecol 1997;37:313-14.
32. Alsulyman OM, Castro MA, Zuckerman E, McGehee W, Goodwin TM. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynaecol 1996;88:644-6.
33. Nagayama K, Izumi N, Miyasaka Y, Saito K, Ono K, Noguchi O, et al. Hemolysis, elevated liver enzymes, and low platelets syndrome associated with primary antiphospholipid antibody syndrome. Intern Med 1997;36:6661-6.
34. Roberts G, Gordon MM, Porter D, Jardine AG, Gibson TW. Acute renal failure complicating HELLP syndrome, SLE and antiphospholipid syndrome; successful outcome using plasma exchange therapy. Lupus 2003;12:251-7.
35. Le Thi Thuong D, Tieulie N, Costedoat N Andreu MR, Wechsler B, Vauthier-Brouzes, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005;64:273-8.
36. Pauzner R, Dulitzky M, Carp H, Mayan H, Kenett R, Farfel Z, et al. Hepatic infarctions during pregnancy are associated with antiphospholipid syndrome and in addition with complete or incomplete HELLP syndrome. J Thromb Haemost 2003;1:1758-63.
37. Gonzalvo FJ, Abecia F, Pinilla I, Izaguirre LB, Olivan JM, Honrubia FM. Central retinal vein occlusion and HELLP syndrome. Acta Ophthalmol Scand 2000;5:596-8.
38. Paternoster DM, Rodi J, Santarossa C, Vanin M, Simioni P, Girolami A. Acute pancreatitis and deep vein thrombosis associated with HELLP syndrome. Minerva Ginecol 1999;51:31-3.
39. Spargo C, Asherson RA. Bilateral deep vein thrombosis, HELLP syndrome and antiphospholipid antibodies. (In Press).
40. Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol 2006;2:81-9.
41. Asherson RA, Cervera R, Merrill JT. Thrombotic microangiopathic antiphospholipid syndromes: a continuum of conditions? Future Rheumatol 2006;1:1-9.
42. Asherson RA. New subsets of the antiphospholipid syndrome in 2006: "PreAPS"(probable APS) and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmunity Reviews 2006;6:76-80.
43. Sinha J, Chowdry I, Sedan S, Barland P. Bone marrow necrosis and refractory HELLP syndrome in a patient with catastrophic antiphospholipid antibody syndrome. J Rheumatol 2002;29:195-7.
44. Koenig M, Roy M, Baccot S, Cuilleron M, De Filippis J-P, Cathebrasl P. Thrombotic microangiopathy with liver, gut and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol 2005;2:166-8.
45. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004;124:567-76.
46. Slofstra SH, Spek A, ten Cate H. Disseminated intravascular coagulation. Haematology 2003;4:295-302.
47. Asherson RA, Espinoza G, Cervera R, Gomez-Puerta JA, Musuruana J, Bucciarelli S, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and hematological characteristics of 23 patients. Ann Rheum Dis 2005;64:943-6.
48. Karmochkine M, Mazoyer E, Marcelli A, Boffa A, Piette JC. High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation. Thromb Hemost 1996;75:971.
49. Bird AG, Lendrum R, Asherson RA, Hughes GRV. Disseminated intravascular coagulation, antiphospholipid antibodies and ischemic necrosis of extremities. Ann Rheum Dis 1987;46:251-5.
50. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
51. Mackworth-Young C. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004;136:393-401.
52. Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 1982;60:1030-7.
53. Prapotnik S, Blank M, Levy Y. Antiendothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 2001;13:203-10.
54. Romani DW, Fijnheer R, Brinkman HJ, Kersting S, Hene RJ, van Mourik JA. Endothelial cell activation in thrombotic thrombocytopenic purpura (TTP). Br J Haematol 2003;123:522-7.
55. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997;89:1224-34.
56. Dang CT, Magid MS, Weksler B, Chadburn A, Laurence J. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood 1999;93:1264-70.
57. Simatov R, La Sala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon J, et al. Activation of cultured endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-19.
58. Meroni PL, Raschi E, Camera, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:237-40.
59. Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the antiphospholipid syndrome. Biomed Pharmacother 2003;7:282-6.
60. Pierangeli SS, Chen PP, Gonzales EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment ana pathogenic mechanisms. Curr Opin Hematol 2006;13:366-75.
61. Pierangeli SS. In search for a receptor for antiphospholipid antibodies on target cells. J Thromb Haemost 2006;4:1678-9.
62. Hulstein JJ, van Runnard Heimel PJ, Franx A, et al. Acute activation of the endothelium results in increased levels of active Von Willebrand factor in HELLP syndrome. J Thromb Haemost 2006;4:2569.
63. 2glycoprotein I and induce endothelial cell activation. Arthritis Rheum 1997;40:551-61.
64. Pierangeli S, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997- 2000.
65. Gharavi AE, Pierangeli SS, Colden-Stanfield M, et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999;163:2922-7.
66. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000;84:388-95.
67. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001;88:245-50.
68. Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli J, et al. E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2002;1:843-8.
69. Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000;43:55-64.
70. Forastiero RR, Martinuzzo ME, De Larranaga G. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus 2005;14:129-36.
71. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role far monocyte tissue factor expression. Arthritis Rheum 1997;40:834-41.
72. Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-81.
73. Dobado-Barrios M, Lopez-Perrara C, Velasco F, Aguirre MA, Turres A, Cuadrado MJ, et al. Increased levels of TF mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999;82:1578-82.
74. Martini F, Farsi A, Gori AM, Boddi M, Fedi S, Domeneghetti MP, et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus 1996;5:206-11.
75. Zhou H, Woldberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004;104:2353-8.
76. 2glycoprotein I antibodies. Thromb Haemost 2002;88:851-7.
77. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52:1545-54.
78. 2glycoprotein I antibodies. Int Immunol 2004;16:1632-41.
79. López-Pedrera C, Buendia P, Cuadrado MJ, Siendones E, Aguirre MA, Barbarroja N, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54:301-1153.
80. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. C3 activation is required for anti-phospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20.
81. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61:46-50.
82. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphophospholipid syndrome. J Clin Invest 2003;112:1644-54.
83. Girardi G, Redecha P, Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222.
84. Pierangeli SS, Girardi G, Vega-Ostertag ME, Liu X, Espinola RG, Salmon J, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-4.
85. 2- glycoprotein I is complement-dependent and requires a priming factor. Blood 2005;106:2340-6.
86. Carbone J, Oerra M, Rodriguez-Mahou M, Rodriguez-Peres C, Sanchez Ramon S, Seoane E, et al. Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus 1999;8:274-8.
87. Munakata Y, Saito T, Matsuda K, et al. Detection of complement-Fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 2000;83:728-31.
88. Davis WD, Brey RL, Seino J, Shibata S, Sasaki T. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol 1992;10:455-60.